Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD

Conclusion: This first study of MART in COPD found that budesonide/formoterol MART is similarly effective as fluticasone/salmeterol fixed-dose therapy in moderate-severe COPD patients, at a lower daily inhaled corticosteroid dosage.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Muiser, S., Imkamp, K., Seigers, D., Halbersma, N., Vonk, J., Luijk, B., Braunstahl, G., Van Den Berg, J. W., Kroesen, B., Kocks, J., Heijink, I., Reddel, H., Kerstjens, H., Van Den Berge, M. Tags: 05.01 - Airway pharmacology and treatment Source Type: research